Division of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Biol Blood Marrow Transplant. 2019 Dec;25(12):2408-2415. doi: 10.1016/j.bbmt.2019.07.015. Epub 2019 Jul 17.
Vulvovaginal graft-versus-host disease (GVHD) is an underdiagnosed and poorly recognized complication of hematopoietic stem cell transplantation (HSCT). Previous studies have reported findings restricted to predominantly adult populations. We report a case series of pediatric and young adult vulvovaginal GVHD, which was identified in 19 patients (median age, 11.8 years; range, 2.4 to 21.9 years) out of a total 302 female patients who underwent transplantation over an 8-year period at a pediatric HSCT center. The majority of patients had concomitant nongenital GVHD; only 1 patient had isolated vulvovaginal GVHD. The median time from bone marrow transplantation to diagnosis of vulvovaginal GVHD was 30 months (range, 2.3 to 97.5 months). A high percentage of the patients in our series were without vulvar or vaginal symptoms (n = 8; 42%), even though 17 patients (89%) presented with grade 3 disease based on current adult grading scales. Vulvar examination findings most frequently included interlabial and clitoral hood adhesions (89%), loss of architecture of the labia minora or clitoral hood (42%), and skin erosions or fissures (37%). Only 5 patients underwent a speculum exam, none of whom had vaginal GVHD. Examination findings of primary ovarian insufficiency (POI) can overlap with those of GVHD, and 6 patients (32%) in our cohort were diagnosed with POI. Only 1 patient was on systemic hormone replacement therapy at the time of vulvovaginal GVHD diagnosis. The majority of patients (n = 16) were treated with topical steroid therapy, with a median time to response of 43 days. Five patients (26%) had a complete response to therapy, and 10 patients (53%) had a partial response. This case series provides valuable insight into pediatric and young adult vulvovaginal GVHD and highlights the need for increased screening for vulvar disease in this population.
外阴阴道移植物抗宿主病(GVHD)是造血干细胞移植(HSCT)后一种诊断不足且认识较差的并发症。既往研究的报道结果主要局限于成人人群。我们报告了一组儿科和青年女性外阴阴道 GVHD 的病例系列,这些患者来自于一家儿科 HSCT 中心在 8 年内接受移植的 302 例女性患者中的 19 例(中位年龄 11.8 岁;范围 2.4 至 21.9 岁)。大多数患者同时存在非生殖器 GVHD;仅有 1 例患者存在孤立性外阴阴道 GVHD。从骨髓移植到诊断外阴阴道 GVHD 的中位时间为 30 个月(范围 2.3 至 97.5 个月)。我们的系列中有很大比例的患者没有外阴或阴道症状(n=8;42%),尽管根据目前的成人分级标准,17 例(89%)患者存在 3 级疾病。外阴检查结果最常包括阴唇间和阴蒂包皮粘连(89%)、小阴唇或阴蒂包皮结构丧失(42%)和皮肤糜烂或皲裂(37%)。仅有 5 例患者接受了阴道镜检查,均未发现阴道 GVHD。原发性卵巢功能不全(POI)的检查结果可能与 GVHD 重叠,我们的队列中有 6 例(32%)患者被诊断为 POI。仅 1 例患者在诊断外阴阴道 GVHD 时正在接受全身激素替代治疗。大多数患者(n=16)接受了局部类固醇治疗,中位反应时间为 43 天。5 例(26%)患者对治疗有完全反应,10 例(53%)患者有部分反应。该病例系列提供了有关儿科和青年女性外阴阴道 GVHD 的宝贵见解,并强调需要增加对此人群外阴疾病的筛查。